HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q3 2019 13F Holders as of 30 Sep 2019

Type / Class
Equity / COM
Total 13F shares
22,399,256
Share change
+9,425,489
Total reported value
$14,978,000
Price per share
$0.67
Number of holders
42
Value change
+$4,656,573
Number of buys
21
Number of sells
21

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q3 2019

As of 30 Sep 2019, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 42 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 22,399,256 shares. The largest 10 holders included Stonepine Capital Management, LLC, Nantahala Capital Management, LLC, FMR LLC, PERKINS CAPITAL MANAGEMENT INC, PRICE T ROWE ASSOCIATES INC /MD/, Alyeska Investment Group, L.P., VANGUARD GROUP INC, BlackRock Inc., Sio Capital Management, LLC, and Diametric Capital, LP. This page lists 42 institutional shareholders reporting positions in this security for the Q3 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.